Clinical Trial: A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07725796) titled 'A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC' on July 21.

Brief Summary: This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Bladder (Urothelial, Transitional Cell) Cancer NMIBC Urothelial Carcinoma Bladder Urothelial Carcinoma in Situ Urothelial Carcinoma Recurrent Urothelial Carcinoma of the Urinary Bladder...